Company news

Sumitomo Pharma Co.Ltd. news in 2026

Sumitomo Pharma Co.Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026

October 30, 2026

Supplementary Financial Data (IFRS) for the Six Months Ended September 30, 2026

October 30, 2026

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 [IFRS]

October 30, 2026

Sumitomo Pharma Announces Variances Between H1 FY2026 Financial Forecasts and Actual Results and Revisions to FY2026 Financial Forecasts

October 30, 2026

Sumitomo Pharma Announces Revision of Its Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2027

October 30, 2026

Presentation Material (Conference on Q2 FY2026 Financial Results

October 30, 2026

Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements

August 28, 2026

Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)

August 11, 2026

Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”

August 6, 2026

Regarding a Report Concerning Sumitomo Pharma

August 4, 2026

Presentation Material (Conference on Q1 FY2026 Financial Results)

July 31, 2026

Matters Concerning Controlling Shareholders, Etc.

June 25, 2026

Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026

June 1, 2026

Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change

May 31, 2026

New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH

May 18, 2026

May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）

May 15, 2026

Sumitomo Pharma: Posted Conference on FY2025 Financial Results

May 15, 2026

May 13, 2026 Conference on FY2025​ Financial Results（PDF/1,054KB）

May 13, 2026

Presentation Material (Conference on FY2025​ Financial Results)

May 13, 2026

Sumitomo Pharma Submits Partial Change Application in Japan to Add Pediatric Dosage and Administration for LATUDA in Schizophrenia

March 30, 2026

Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa

March 23, 2026

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan

March 5, 2026

May. 02, 2026 Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma - transcript（PDF/6,280KB）

March 4, 2026

May. 03, 2026 Conference on Boost 2028 - Accelerating Strong Sumitomo Pharma -（PDF/3,386KB）

March 2, 2026

Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -)

March 2, 2026

Sumitomo Pharma Announces Revisions to Its Financial Forecasts

March 2, 2026

Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma

March 2, 2026

Announcement of Filing of Shelf Registration Statement for Issuance of New Shares

March 2, 2026

Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)

February 26, 2026

Feb. 17, 2026 R&D Meeting transcript（PDF/5,926KB）

February 19, 2026

Feb. 17, 2026 R&D Meeting（PDF/2,493KB）

February 16, 2026

Jan. 30, 2026 Conference on Q3 FY2025 Financial Results transcript（PDF/3,079KB）

February 2, 2026

Sumitomo Pharma: Posted Conference on Q3 FY2025 Financial Results

February 2, 2026

Calls in 2026

Decks in 2026